Dedifferentiated Liposarcoma Treatment Market and Factors Behind its Growing Landscape – Industry Analysis by Top Vendors, Size, Growth Factors and Forecast to 2026

SEATTLE, March 25, 2021, (PHARMIWEB) — Global Dedifferentiated Liposarcoma Treatment Market – Insights

Liposarcoma is a rare cancer of connective tissues that resemble fat cells under a microscope. Dedifferentiated liposarcoma (DDLS) is a high-grade subtype of liposarcoma that progresses from well-differentiated liposarcoma. The tumors of DDLS are generally present in the retroperitoneal/abdominal cavity followed by the limbs. Although the exact reason for development of these tumors is not understood, genetic mutations is credited in generation of these tumors.

Complete excision and removal of tumors by various therapies such as liposuction and targeted immunotherapy are the widely adopted approaches for the treatment of DDLS. Although the disease has no gender inclination, it is commonly found in patients over 50 years of age.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1532

Global Dedifferentiated Liposarcoma Treatment Market: Drivers

The global dedifferentiated liposarcoma treatment market is expected to witness a moderate growth rate, owing to low prevalence of DDLS worldwide. For instance, according to the World Health Organization, 2016, the prevalence rate of well-differentiated liposarcoma is 2.5 per million and that for DDLS is 18% of the total incidence of liposarcoma worldwide.

High prevalence of genetic disorders is expected to aid in growth of the global dedifferentiated liposarcoma treatment market. For instance, according to Genetics Education Center, University of Kansas Medical Center, 2012, 15% of all the cancer have an inherited susceptibility as well as 12% of the hospital admissions in the U.S. accounted for treatment of genetic causes in 2013. Moreover, according to a report published by Massachusetts General Hospital in 2017, liposarcoma affected around 375,000 people worldwide.

Moreover, government and non-government organizations are focused on increasing awareness regarding availability of treatment for liposarcoma, which is also expected to aid in growth of the market. For instance, the Massachusetts General Hospital Cancer Center’s Liposarcoma Genome Project focuses on R&D in well-differentiated and dedifferentiated liposarcoma in order to offer novel treatment options.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Dedifferentiated Liposarcoma Treatment Market Research Report: https://bit.ly/3d3nEY6

Global Dedifferentiated Liposarcoma Treatment Market: Restraints 

High cost of treatment procedures and low accessibility due to the rareness of CDI are some of the factors that hinder growth of the market.

Global Dedifferentiated Liposarcoma Treatment Market Taxonomy:

On the basis of treatment type, the global dedifferentiated liposarcoma treatment market is segmented into:

• Chemotherapy
• Immunotherapy
• Radiation Therapy

On the basis of end-user, the global dedifferentiated liposarcoma treatment market is segmented into:

• Hospitals
• Multispecialty Clinics
• Cancer Treatment & Rehabilitation Centers

On the basis of region, the global dedifferentiated liposarcoma treatment market is segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1532

Global Dedifferentiated Liposarcoma Treatment Market: Regional Analysis

North America is expected to account for the largest market share in the global dedifferentiated liposarcoma treatment market over the forecast period. This is attributed to funding for R&D of novel therapies for the treatment of DDLS. For instance, the Sarcoma Foundation of America offers funds for R&D in various types of sarcomas.

High incidence of DDLS is expected to propel growth of the market in Asia Pacific. For instance, according to the Journal of Blood & Lymph 2013, in India, around 35% of patients suffering with sarcoma died due to DDLS, wherein the total number of deaths as a result of sarcoma was reported to be 328 patients in 2012.

Global Dedifferentiated Liposarcoma Treatment Market: Segment Analysis

Among treatment types, the chemotherapy segment is expected to hold dominant position in the global dedifferentiated liposarcoma treatment market. This is attributed to widespread availability of cancer drugs worldwide. For instance, according to the British Medical Journal, the European Medical Agency approved the use of 48 cancer drugs for 68 indications in Europe. Moreover, several drugs are nearing patent expiry, which is expected to boost production of generics in the market.

The immunotherapy segment is expected to witness marginal growth in the market over the forecast period. This is attributed to R&D in targeted cell therapy and other immunotherapies that have lower side effects compared to chemotherapy. For instance, according to Memorial Sloan Kettering Cancer Center 2015, checkpoint inhibitor-based immunotherapy is being effectively tested against DDLS.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/dedifferentiated-liposarcoma-treatment-market-1532

Global Dedifferentiated Liposarcoma Treatment Market: Competitive Landscape 

Major players operating in the global dedifferentiated Liposarcoma treatment market include, Johnson & Johnson Services, Inc., Eli Lily & Company, Novartis AG, Pfizer, Inc., and Sanofi SA.

Global Dedifferentiated Liposarcoma Treatment Market: Key Developments  

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in July 2017, Karyopharm Therapeutics, Inc. cleared Phase II clinical trial for Selinexor, an orally administered inhibitor of CRM1 that is indicated for the treatment of unresectable DDLS.

Table of Content

Global Dedifferentiated Liposarcoma Treatment Market Research Report
Section 1: Global Dedifferentiated Liposarcoma Treatment Industry Overview
Section 2: Global Economic Impact on Dedifferentiated Liposarcoma Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Dedifferentiated Liposarcoma Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Dedifferentiated Liposarcoma Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837